Literature DB >> 8790439

Chronic control of high blood pressure in the spontaneously hypertensive rat by delivery of angiotensin type 1 receptor antisense.

S N Iyer1, D Lu, M J Katovich, M K Raizada.   

Abstract

The renin-angiotensin system plays a crucial role in the development and establishment of the hypertensive state in the spontaneously hypertensive (SH) rat. Interruption of this system's activity by pharmacological means results in the lowering of blood pressure (BP) and control of hypertension. However, such means are temporary and require the continuous use of drugs for the control of this pathophysiological state. Our objective in this investigation was to determine if a virally mediated gene-transfer approach using angiotensin type 1 receptor antisense (AT1R-AS) could be used to control hypertension on a long-term basis in the SH rat model of human essential hypertension. Injection of viral particles containing AT1R-AS (LNSV-AT1R-AS) in 5-day-old rats resulted in a lowering of BP exclusively in the SH rat and not in the Wistar Kyoto normotensive control. A maximal anti-hypertensive response of 33 +/- 5 mmHg was observed, was maintained throughout development, and still persisted 3 months after administration of LNSV-AT1R-AS. The lowering of BP was associated with the expression of AT1R-AS transcript and decreases in AT1-receptor in many peripheral angiotensin II target tissues such as mesenteric artery, adrenal gland, heart, and kidney. Attenuation of angiotensin II-stimulated physiological actions such as contraction of aortic rings and increase in BP was also observed in the LNSV-AT1R-AS-treated SH rat. These observations show that a single injection of LNSV-AT1R-AS normalizes BP in the SH rat on a long-term basis. They suggest that such a gene-transfer strategy can be successfully used to control the development of hypertension on a permanent basis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8790439      PMCID: PMC38537          DOI: 10.1073/pnas.93.18.9960

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

Review 1.  Angiotensin II receptors and angiotensin II receptor antagonists.

Authors:  P B Timmermans; P C Wong; A T Chiu; W F Herblin; P Benfield; D J Carini; R J Lee; R R Wexler; J A Saye; R D Smith
Journal:  Pharmacol Rev       Date:  1993-06       Impact factor: 25.468

2.  Modulation of blood pressure and the renin-angiotensin system in transgenic and spontaneously hypertensive rats afer ovariectomy.

Authors:  J Bachmann; J Wagner; C Haufe; A Wystrychowski; A Ciechanowicz; D Ganten
Journal:  J Hypertens Suppl       Date:  1993-12

3.  Intracerebroventricular administration of AT1 receptor antisense oligonucleotides inhibits the behavioral actions of angiotensin II.

Authors:  R R Sakai; P F He; X D Yang; L Y Ma; Y F Guo; J J Reilly; C N Moga; S J Fluharty
Journal:  J Neurochem       Date:  1994-05       Impact factor: 5.372

4.  Vascular reactivity to phenylephrine and angiotensin II in hypertensive rats associated with insulin resistance.

Authors:  S N Iyer; M J Katovich
Journal:  Clin Exp Hypertens       Date:  1996-02       Impact factor: 1.749

5.  Regulation of angiotensin II type 1 receptor mRNA in neuronal cultures of normotensive and spontaneously hypertensive rat brains by phorbol esters and forskolin.

Authors:  D Lu; C Sumners; M K Raizada
Journal:  J Neurochem       Date:  1994-06       Impact factor: 5.372

Review 6.  Angiotensin II receptor antagonists: a new approach to blockade of the renin-angiotensin system.

Authors:  P M Kang; A J Landau; R T Eberhardt; W H Frishman
Journal:  Am Heart J       Date:  1994-05       Impact factor: 4.749

7.  Increased angiotensin II type-1 receptor gene expression in neuronal cultures from spontaneously hypertensive rats.

Authors:  M K Raizada; D Lu; W Tang; P Kurian; C Sumners
Journal:  Endocrinology       Date:  1993-04       Impact factor: 4.736

8.  Angiotensin II type 1 receptor mRNA levels in the brains of normotensive and spontaneously hypertensive rats.

Authors:  M K Raizada; C Sumners; D Lu
Journal:  J Neurochem       Date:  1993-05       Impact factor: 5.372

9.  Prevention of genetic hypertension by early treatment of spontaneously hypertensive rats with the angiotensin converting enzyme inhibitor captopril.

Authors:  J N Wu; K H Berecek
Journal:  Hypertension       Date:  1993-08       Impact factor: 10.190

10.  Antisense inhibition of AT1 receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin.

Authors:  R Gyurko; D Wielbo; M I Phillips
Journal:  Regul Pept       Date:  1993-12-10
View more
  12 in total

Review 1.  Designing antisense to inhibit the renin-angiotensin system.

Authors:  D Mohuczy; M I Phillips
Journal:  Mol Cell Biochem       Date:  2000-09       Impact factor: 3.396

2.  Endothelial cell-specific aryl hydrocarbon receptor knockout mice exhibit hypotension mediated, in part, by an attenuated angiotensin II responsiveness.

Authors:  Larry N Agbor; Khalid M Elased; Mary K Walker
Journal:  Biochem Pharmacol       Date:  2011-06-13       Impact factor: 5.858

3.  Prevention of renovascular and cardiac pathophysiological changes in hypertension by angiotensin II type 1 receptor antisense gene therapy.

Authors:  J R Martens; P Y Reaves; D Lu; M J Katovich; K H Berecek; S P Bishop; M K Raizada; C H Gelband
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

Review 4.  Genetic targeting of the renin-angiotensin system for long-term control of hypertension.

Authors:  Beverly L Metcalfe; Mohan Raizada; Michael J Katovich
Journal:  Curr Hypertens Rep       Date:  2002-02       Impact factor: 5.369

Review 5.  Gene therapy of hypertensive vascular injury.

Authors:  Y Chu; F M Faraci; D D Heistad
Journal:  Curr Hypertens Rep       Date:  2000-02       Impact factor: 5.369

6.  Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II.

Authors:  P J Pagano; J K Clark; M E Cifuentes-Pagano; S M Clark; G M Callis; M T Quinn
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

7.  Blunting of cardioprotective actions of estrogen in female rodent heart linked to altered expression of cardiac tissue chymase and ACE2.

Authors:  Jacqueline S da Silva; Daniele Gabriel-Costa; Hao Wang; Sarfaraz Ahmad; Xuming Sun; Jasmina Varagic; Roberto T Sudo; Carlos M Ferrario; Louis J Dell Italia; Gisele-Zapata Sudo; Leanne Groban
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2017 Jul-Sep       Impact factor: 1.636

Review 8.  Counter-regulatory renin-angiotensin system in cardiovascular disease.

Authors:  Maria Paz Ocaranza; Jaime A Riquelme; Lorena García; Jorge E Jalil; Mario Chiong; Robson A S Santos; Sergio Lavandero
Journal:  Nat Rev Cardiol       Date:  2019-08-19       Impact factor: 32.419

9.  Determining available strategies for prevention and therapy: Exploring COVID‑19 from the perspective of ACE2 (Review).

Authors:  Liyang Cai; Xi Guo; Yuchen Cao; Peixi Ying; Libing Hong; Yuxi Zhang; Guoguo Yi; Min Fu
Journal:  Int J Mol Med       Date:  2021-02-12       Impact factor: 4.101

Review 10.  Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2.

Authors:  Mahmoud Gheblawi; Kaiming Wang; Anissa Viveiros; Quynh Nguyen; Jiu-Chang Zhong; Anthony J Turner; Mohan K Raizada; Maria B Grant; Gavin Y Oudit
Journal:  Circ Res       Date:  2020-04-08       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.